Blog
-
“Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers” from Diabetes Care
A recently published article in Diabetes Care, Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers, is one of the most comprehensive reviews on the topic in the last several years. Disturbing trends in healthcare disparities for lower income and minority patient populations with diabetic foot ulcers (DFUs) are discussed. Another concern noted […]
-
ADA releases Standards of Care in Diabetes—2023
The American Diabetes Association just released their 2023 version of it’s Standards of Care in Diabetes. The Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes chapter again reflects the latest evidenced-based guidelines on the treatment of the diabetic foot. Some newer recommendations include topical oxygen therapy for recalcitrant diabetic foot ulcers and alpha […]
-
Other Products Page Refresh
We are pleased to announce an update to our “Other Products” page. This page lists products licensed to other companies as well as new product concepts available for licensing. Contact us for further details.
-
New Study Finds Vibration Testing More Reliable than Monofilament over Plantar Calluses
Wynands et al’s recently published “Does plantar skin abrasion affect cutaneous mechanosensation?” brings into focus the importance of plantar callus debridement. This study measured skin thickness, hardness, monofilament threshold and vibration perception threshold (VPT) in healthy participants over plantar calluses before and after “abrasion” (debridement). The intervention group was compared to a matched control group […]
-
ETF128 selected for vibration testing in Benfotiamine clinical trials
The company was please to learn that the ETF128 will be one of the vibration testing methods utilized in an international clinical trial assessing the effects of benfotiamine on patients with diabetic peripheral neuropathy (DPN). This randomized, double-blind, placebo-controlled study will compare benfotiamine 300 mg twice per day to placebo over 12 months. Vibration testing with […]